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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: CoA stenting through theCA in neonates and infantswas feasible safe and
effective in the short-to-mid-term. New procedures should be performed during follow
up to adjust for somatic growth, treat complications or repair intracardiac lesions.
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Background: No devices are currently available in the USA for percutaneous closure
of perimembranous (Pm) ventricular septal defects (VSDs). The earlier device was
withdrawn from clinical trial because of development of heart block possibly related to
over sizing and/or device rigidity. New, softer devices are available for vascular oc-
clusions as the Amplazer Vascular Plug II (AVP II) and the Amplatzer Duct Occluder
II (ADO II). We previously submitted our initial experience in occluding Pm VSDs
using AVP II & ADO II in 10 patients (pts) using AVP II in 6 and ADO II in 4. This is
follow up (f/up) of these pts and additional pt.
Methods: F/up data of these pts. were reviewed speciﬁcally assessing for the devel-
opment of heart block, residual ﬂow through the device, presence of aortic insufﬁciency
(AI) and device embolization or fracture or the occurrence of late adverse events (AE).
Results: Review of F/up data of these pts. was performed speciﬁcally assessing for the
development of heart block, residual ﬂow through the device, presence of aortic
insufﬁciency (AI) and device embolization or fracture or the occurrence of late
adverse events (AE).
Results: F/up clinical evaluations, chest x-rays and echocardiograms were available
for all patients expect 1 who did not undergo chest x ray because of pregnancy. F/up
period ranged from 0-13 months with a median of 5.5 + 5. New AI was seen in 3
patients graded as mild in 1 and trivial in 2. In 1 patient the AI could have been
preexisting and masked by the VSD ﬂow. 1 patient had mild new Tricuspid regur-
gitation. There was no incidence of device fracture or late embolization and no clinical
evidence of hemolysis, sub-acute bacterial endocarditis or any serious AE. No patient
developed heart block. In 1 patient with elongated tunnel type VSD, the device took
the conﬁguration of the defect. 1 patient had residual ﬂow through the device which
disappeared on follow up. I patient has additional small VSD.
Conclusions: In our series, percutaneous closure of PmVSDs using the softer new
generation devices as the AVP II and the ADO II appears to be safe in the short term.
Flow seen through the device usually disappears as the device endothelializes.
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Background: Residual lesions after surgical repair of complex congenital heart dis-
ease (CHD) are poorly tolerated. An exit angiography (EA) after cardiopulmonary
bypass (CPB) has been performed to promptly diagnose residual lesions, which may
result in a change of the management strategy. We report our initial experience with
EA and intraoperative stenting (IOS) in a dedicated hybrid suite (HS).
Methods: Patients (pts) with complex CHD were selected for EA at multidisci-
plinary meetings. All procedures were conducted in a dedicated HS in the OR.
Catheters were advanced through sheaths secured by purse string sutures in the
RVOT, SVC, MPA or ascending aorta. Stent delivery was guided by ﬂuoroscopy
after CPB completion.
Results: From 05/12 to 05/14, EA was performed in 22 pts (median age and weight:
0.9 years and 9.2 kg, respectively) after surgical repair (Glenn operations, uni-
focalization, bioprosthetic valve insertion, complex CoA). Twelve patients (55%)
required IOS with 14 stents implanted in the PAs or descending aorta (1). The decision
to implant a stent was made before hand in 4 pts and only after EA was performed in 8
pts (2 pts had undergone a failed redo surgical PA plasty under CPB after an initial
EA). In all patients, stents were placed in the intended location and resulted in sig-
niﬁcant increase of vessel diameter from a median of 3.7 to 8.5 mm (p< 0.001). There
were no deaths or vascular complications during the procedure. Of those 12 patients
who underwent IOS, 8 pts had an uneventful early postoperative period. Two pts died
in the ICU (1 pt with complex univentricular heart and 1 pt with HLHS in ECMO after
Norwood-Glenn operation) and 1 patient each needed hemodialysis and peri-
cardiocentesis, respectively, not related to EA or IOS. Of those 10 pts in whom IOS
was not performed, surgical results were considered adequate and post-op course was
uneventful.
Conclusions: EA and IOS were feasible, safe and effective. EA should be carefully
planned before surgery in selected patients and may result in changes in management
strategies. IOS probably results in better immediate surgical outcomes.B50 JACC Vol 64/11/Suppl B j SepLeft Atrial Appendage Exclusion
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Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial
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Background: Transcatheter left atrial appendage occlusion (LAAO) is a promising
therapy for stroke prophylaxis in non-valvular atrial ﬁbrillation (NVAF) but its cost-
effectiveness remains understudied.
Methods: A Markov decision analytic model was used to compare cost-effectiveness
of LAAO with 7 alternative strategies: Aspirin alone, Clopidogrel plus Aspirin,
Warfarin, Dabigatran (110 and 150mg), Apixaban, and Rivaroxaban. This model
simulates a cohort of 65-year-old NVAF patients moving between different health
statuses in each Markov cycle of 1 year. The time horizon was lifetime (85 years old).
Health states include AF without event, with event before, ischemic cerebrovascular
events, hemorrhage, myocardial infarction, vascular or non-vascular deaths. To esti-
mate discounted (3%) lifetime costs, quality-adjusted life years (QALYs) and incre-
mental cost-effectiveness ratios (ICERs). Base-case data were derived from ACTIVE,
RE-LY, PROTECT-AF and PREVAIL trials. One-way sensitivity analysis varied by
HAS-BLED scores and time horizons, and probabilistic sensitivity analysis (PSA)
using Monte Carlo simulations were conducted to assess parameter uncertainty.
Results: Compared with Aspirin alone, Clopidogrel plus Aspirin, Warfarin, Dabigatran
110mg, LAAO was cost-effective with an ICER of $3,921, $2,226, $3431, and $58 per
QALY gained, respectively; however, LAAO was dominant to Dabigatran 150mg,
Apixaban, and Rivaroxaban strategies (i.e. less costly and more effective). Sensitivity
analysis demonstrated signiﬁcant performance in ICERs of LAAO against oral antico-
agulant drugs for patients with increasing HAS-BLED scores and within the varied time
horizons (5, 10, and 15 years), and LAAO strategy was cost-effective over 99% of the
Monte Carlo simulation using a cost-effectiveness threshold of US$50,000/QALY.
Conclusions: Transcatheter LAAO strategy is considered cost-effective as compared
with 7 other antithrombotic strategies for prevention of stroke in patients with NVAF
regardless of their risks of ischemic stroke.
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Background:WATCHMAN left atrial appendage (LAA) closure is a novel approach
to preventing stroke in patients with atrial ﬁbrillation (AF) that could reduce the
longer-term risk of bleeding compared with anticoagulation. We compared the tem-
poral incidence of major bleeding beyond the immediate procedural period in the
randomized trials of the device.
Methods: Landmark analyses of time-to-ﬁrst major bleed in the PROTECT-AF,
PREVAIL, and pooled trials were performed for 3 periods: (1) from 8-to-45 days post-
procedure, during which WATCHMAN patients received warfarin; (2) from 46-to-
180 days, during which WATCHMAN patients received dual antiplatelet therapy
(DAPT); and (3) beyond 180 days, when WATCHMAN patients were eligible to
receive aspirin alone. Major bleeding was site-reported and adjudicated as a serious
adverse event by the Clinical Events Committee.
Results: After the periprocedural period, the risk of major bleeding did not differ
signiﬁcantly between study arms when WATCHMAN patients received warfarin or
DAPT. Beyond 6 months, the bleeding risk was signiﬁcantly lower with the device
strategy compared with long-term warfarin (Hazard Ratio [HR] 0.30 [95% Conﬁdence
Interval (CI): 0.17-0.53), a ﬁnding that was consistent across trials (PROTECT-AF:
HR 0.31 [95% CI: 0.16-0.61]; PREVAIL, HR 0.27 [95% CI: 0.09-0.79]).tember 13–17, 2014 j TCT Abstracts/Left Atrial Appendage Exclusion
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: LAA closure with the WATCHMAN reduced bleeding compared with
warfarin after post-procedural adjunctive therapy was completed. This should be
considered in the overall risk-beneﬁt analysis when selecting a strategy for stroke
prevention in patients with AF.
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Background: To investigate the safety and efﬁcacy of left atrial appendage occlusion
(LAAO) with the Amplatzer Cardiac Plug (ACP) for stroke prevention in patients with
atrial ﬁbrillation (AF).
Methods: Data from consecutive patients treated in 22 centers were collected. Patients
who underwent successful single LAAO and who were on aspirin monotherapy or no
therapy at last follow-up were included in the study.
Results: A total of 627 patients (age 758 years) fulﬁlled the inclusion criteria. Of those,
579were on aspirin (92%) and 48 received no treatment (8%) at last follow-up. Themean
CHA2DS2-VASc score was 4.41.5 (annual risk of thromboembolism ¼ 5.62.7%),
and the mean HASB-LED Score was 3.21.2 (annual risk of major bleeding ¼
5.73.9%). There were 3 strokes (0.5%), 1 transient ischemic attack (TIA) (0.2%), and 8
major bleedings (1.3%) in the periprocedural period. The median (IQR) follow-up was
16.2 (9.7-26.2) months, accumulating 981 patient years. A total of 21 deaths were re-
ported during follow-up, which were not reported as device related. There were 3 strokes
(0.5%), 6 TIAs (1.0%), and 5 major bleedings (0.8%) during follow-up. The annual rate
of systemic thromboembolism was 1.33% (13/981 patient-years), which is a 76.4% risk
reduction compared to the annual predicted rate. The annual rate of major bleeding was
1.33% (13/981 patient-years), which is a 76.5% risk reduction.
Conclusions: In this multicenter study, LAAO with the ACP and aspirin or no therapy
at follow-up was effective in preventing thromboembolism, and was combined with a
reduction of major bleeding events.
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Echocardiography From the Left Atrium
Ramez El Khoury1, JEAN MARC RAYMOND1, Jeannot Potvin1, Charbel Naim1,
Jean Bernard Masson1
1Centre Hospitalier de l’Université de Montréal, Montreal, Quebec
Background: Percutaneous left atrial appendage (LAA) occlusion is commonly
performed under general anesthesia and trans-esophageal echocardiography (TEE)
guidance. Intra-cardiac echocardiography (ICE) offers several advantages over TEE
for procedural guidance; however experience is limited with LAA occlusion. In
previous reports of LAA closure under ICE guidance, ICE was performed from theJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Leright atrium or coronary sinus where complete visualization of the LAA anatomy is
uncertain. We sought to evaluate the feasibility, efﬁcacy and safety of LAA occlusion
using ICE guidance from the left atrium (LA).
Methods: Twenty-three patients with AF, signiﬁcant risk for stroke and long-term
contra-indication for anticoagulation underwent LAA closure with the Amplatzer Car-
diacPlugTM(St.JudeMedical Inc.) under conscious sedation and ICEguidance.The ICE
catheter and ACP delivery sheath were advanced into the LA through separated trans-
septal punctures. Baseline patient characteristics, procedural and follow-up data were
prospectively recorded. Clinical and TEE follow-up was done at 3 months after the
procedure. Procedural successwas deﬁned as the implantation of the closure device at the
intended delivery site with adequate (grade 3 ormore by angiography and ICE) occlusion
Results: Procedural success was achieved in 22 of 23 patients (96%) with a mean
procedural time of 105 +/- 27 minutes; challenging anatomy was the reason of failure.
Median hospital stay was 1 day. No major procedural complication occurred however
two patients died during the follow up period. In both cases, death was not related to the
procedure or device. At 3-months, total LAA occlusion was observed in the 17 device-
recipient survivors who had completed TEE follow-up. In all cases, ICE provided
adequate procedural guidance, closure assessment and LAA and device visualization,
including their relation with adjacent structures. Best imaging of the LAAwas available
with the ICE catheter placed in a mid-LA location or just above the mitral plane.
Conclusions: Initial experience suggests that LAA occlusion with the Amplatzer
Cardiac PlugTM under ICE guidance from the left atrium in conscious patients is
feasible, reproducible and safe.
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Background: Left atrial appendage (LAA) device imaging after percutaneous closure
for atrial ﬁbrillation is important to assess for residual leak, device-associated thrombus,
device positioning, surrounding structures, and pericardial effusion. Cardiac computed
tomography angiography (CCTA) is well suited to assess these features non-invasively.
Methods: We report our pilot consecutive series of follow-up CCTA after LAA
closure with the Amplatzer Cardiac Plug (ACP), Amulet, or Watchman devices, at
Vancouver General Hospital. Patients were treated with aspirin indeﬁnitely, and
clopidogrel for 1-3 months following LAA closure. Transthoracic echocardiograms
were routinely performed at 1 month and CCTA at 1-6 months post-procedure for
clinical surveillance in this series of patients. Prospective cardiac-gated CCTA were
performed with Toshiba 320-slice or Siemens 2nd generation 128-slice dual source
scanners, and images were interpreted with the Vitrea software. GFR < 40 was an
exclusion. We assessed for atrial-side device thrombus, residual contrast leak into the
LAA, pericardial effusion, and device dimensions.
Results: Twenty-ﬁve patients underwent CCTA at a mean of 157  143 days
following LAA closures (13 ACP, 8 Amulet, and 4 Watchman). Average age was
75.5  9.8 years, and CHADS2 score was 3.2  1.3. All patients had contraindica-
tions to anticoagulation for atrial ﬁbrillation, and were treated with dual antiplatelet
therapy post-procedure. All devices were visualized within the LAA on CCTA. No
pericardial effusion was seen on CCTA follow-up. Only one patient had thrombus on
the atria-side of the device. Sixty-ﬁve percent had residual leak into the LAA on
CCTA at follow-up. Device measurements on CCTA and correlation to TEE mea-
surements post-procedure and device dimensions will be presented.
Conclusions: CCTA is a useful non-invasive imaging test for clinical surveillance
after percutaneous LAA closure. Assessments of device position, atrial-side thrombus,
pericardial effusion, and residual patency into the LAA are well visualized on CCTA.
However, residual LAA patency is seen frequently on CCTA, and correlation to the
degree of TEE residual leak should be further explored.
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Background: WATCHMAN is the most studied LAA device clinically with >2000
implantations and >5000 patient-years of follow-up. Currently, a new generation of
Watchman has been designed to further improve implant performance. Similar to the
current generation (CG-WM), the next generation (NG-WM) also has a self-expanding
nitinol frame structure, which is covered with a permeable polyester fabric membrane and
deployed using a 12F delivery systemwith a 14F access sheath. The key design changes in
theNG-WMinclude18struts (vs. 10 inCG-WM), anatraumatic closeddistal end (vs. open
end inCG-WM), and reduced length of theNG-WM.TheNG-WMcanbe redeployedafter
either full or partial recapture. In contrast, the CG-WMhas to be replaced if a full recapture
is needed. The present study is aimed to test the NG-WM device in a canine LAAmodel.
Methods: A total of 14 dogs were used in the study. Under TEE at 0, 45, 90 and 135
views and x-ray guidance, both CG-WM and NG-WM were appropriately sized to be
10-20% larger than the LAA ostium.ft Atrial Appendage Exclusion B51
